Apply for Prevymis (Letermovir) Copay Assistance

Prevymis copay assistance means outside financial help that can lower what you pay for Prevymis (letermovir). Depending on your insurance, that help may come from a manufacturer copay card, the manufacturer’s patient assistance program, or a grant from an independent charitable foundation.

QuickRx Specialty Pharmacy does the legwork for you. Our patient navigators check your insurance, look for the options you may qualify for, prepare and submit the applications on your behalf, and keep track of renewals, at no cost to you.*

To get started, call QuickRx at (917) 830-2525 or complete the form on this page.

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

Each program sets its own rules. Manufacturer copay cards are generally limited to patients with commercial or private insurance. Federal guidance from the HHS Office of Inspector General explains that manufacturer copay coupons cannot be used by patients whose drug is paid for by federal health care programs such as Medicare or Medicaid.

Patients with Medicare, Medicaid or no insurance may still have options, such as the manufacturer’s patient assistance program or an independent foundation grant for their condition. These usually have their own requirements, such as income and insurance documents.

QuickRx reviews your situation and tells you which options you may qualify for. Call (917) 830-2525 to get started.

Source: HHS Office of Inspector General, Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons (September 2014).

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

Merck’s Prevymis website describes a Merck Access Program that provides information on co-pay assistance options for eligible patients, and a co-pay coupon link. Terms, amounts and eligibility are set by Merck.*

Manufacturer copay coupons generally cannot be used by patients whose prescription is paid for by a federal health care program such as Medicare or Medicaid.

Manufacturer program details are from Merck’s public Prevymis and Merck Patient Assistance Program web pages, accessed September 30, 2026. Merck sets and may change its own terms; QuickRx is not affiliated with Merck.

Source: HHS Office of Inspector General, Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons (September 2014).

Merck lists Prevymis in the Merck Patient Assistance Program. According to Merck’s website, applicants must be US residents with a valid prescription from a US-licensed provider, must not have insurance or other coverage for the medicine, and must meet household income limits that Merck publishes and may change.*

QuickRx can help you understand the application. Call (917) 830-2525.

Manufacturer program details are from Merck’s public Prevymis and Merck Patient Assistance Program web pages, accessed September 30, 2026. Merck sets and may change its own terms; QuickRx is not affiliated with Merck.

No. There is never any cost for QuickRx’s copay assistance services. You will not receive a bill from QuickRx for checking your eligibility, preparing applications, or handling renewals.*

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

No. Lexidrug lists no generic letermovir available in the United States as of September 2026. Prevymis is the only US brand.

Source: Lexidrug, letermovir monograph, Generic Available (US) and Dosage Forms: US (accessed 9/30/2026). Availability may change.

Lexidrug lists an Average Wholesale Price (AWP) of $337.50 per Prevymis tablet for both the 240 mg and 480 mg strengths. At one tablet a day, 30 days works out to about $10,125 at AWP. Oral pellet packets are listed at $14.05 (20 mg) and $84.31 (120 mg) each.*

What you actually pay depends on your insurance and any help you may qualify for. Call (917) 830-2525 for a free benefits check.

AWP (Average Wholesale Price) is a Medi-Span benchmark published in Lexidrug (letermovir monograph, accessed 9/30/2026). It is a reference price only, not a retail price, not a quote and not what you will pay. The 30-day figure is simple math (per-tablet AWP x 30) for illustration only.

Prevymis (letermovir) is an antiviral medicine, first approved by the FDA on November 8, 2017. It is used to prevent cytomegalovirus (CMV) infection and disease in two groups of transplant patients:

Stem cell (hematopoietic cell) transplant: adults and children 6 months and older weighing at least 6 kg who are CMV-seropositive recipients of an allogeneic transplant.

Kidney transplant: high-risk adults and children 12 years and older weighing at least 40 kg, where the donor is CMV-positive and the recipient is CMV-negative (D+/R-).

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.

For adults, the usual dose is 480 mg once a day, by mouth or by IV. After a stem cell transplant, it is usually started between day 0 and day 28 and continued through day 100; some patients may continue through day 200. After a high-risk kidney transplant, it is usually started between day 0 and day 7 and continued through day 200. Your transplant team may lower the dose if you also take cyclosporine.

Tablets: take with or without food and swallow whole. Oral pellets: do not crush or chew; mix with 1 to 3 teaspoons of soft food (such as applesauce or yogurt) that is at or below room temperature, and take within 10 minutes. IV: used only for patients who cannot take it by mouth, and switched to oral as soon as possible.

Always follow the exact dose and schedule your transplant team gives you.

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.

Kidney: no dose change is needed when CrCl is above 10 mL/minute. The labeling gives no dose advice for CrCl of 10 or less or for dialysis, though Lexidrug notes a change is unlikely because very little leaves the body in urine. For the IV form, kidney function is watched closely when CrCl is below 50 mL/minute, because an ingredient in the IV solution can build up.

Liver: no change for mild or moderate liver problems (Child-Pugh A or B). Use is not recommended with severe liver problems (Child-Pugh C).

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.

In adults, side effects reported in more than 10% of patients include nausea (27%), diarrhea (26%), vomiting (19%), swelling in the legs or arms (14%), cough (14%), headache (14%), tiredness (13%), heart rhythm changes (13%, including atrial fibrillation 3% and fast heartbeat 4%), stomach pain (12%) and low platelet counts.

Call your doctor right away for a fast or abnormal heartbeat, swelling, changes in how much you urinate, signs of infection, unexplained bruising or bleeding, or signs of an allergic reaction. With the IV form, also report ringing in the ears or hearing changes.

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.

Other viruses: Prevymis only works against CMV. Your team may add another antiviral (such as acyclovir) to protect against herpes simplex virus.

Resistance: CMV can become resistant to letermovir through changes in a viral gene called UL56.

IV form: contains hydroxypropyl betadex; it is meant for patients who cannot take pills and, if possible, should not be used for more than 4 weeks.

Older adults: in clinical trials, 15% of patients were 65 or older, and no differences in safety or effectiveness were seen compared with younger patients.

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.

Yes, many. Prevymis must not be taken with pimozide or ergot medicines, and must not be combined with pitavastatin or simvastatin when you also take cyclosporine.

It can raise levels of several transplant medicines, including cyclosporine and sirolimus, and your team may monitor tacrolimus levels. It can lower levels of voriconazole and may affect warfarin. Atorvastatin is limited to 20 mg a day with Prevymis, and is not recommended at all when cyclosporine is also used. Carbamazepine should be avoided.

Tell every doctor and pharmacist about every medicine and supplement you take. QuickRx pharmacists can review your list; call (917) 830-2525.

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.

Your transplant team will check for CMV coming back (reactivation) and will check your kidney function (serum creatinine), especially if you get the IV form and your CrCl is below 50 mL/minute.

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.

Some animal studies showed harmful effects, and it is not known whether letermovir passes into breast milk. Talk with your transplant team about the risks and benefits if you are pregnant, planning a pregnancy or breastfeeding.

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.

Yes, as an off-label use. Lexidrug lists letermovir as an alternative for CMV prevention in at-risk liver, lung, heart and kidney transplant recipients, supported by the Fourth International Consensus Guidelines on CMV in Solid Organ Transplantation (2025), mainly for patients who cannot tolerate other antivirals such as valganciclovir.

Off-label means the use is not approved by the FDA for that condition. Insurance coverage and assistance eligibility for off-label use may differ from approved uses.

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.

Store tablets at room temperature, 20°C to 25°C (68°F to 77°F), in the original container to protect from moisture. Store oral pellets in the original packet at the same temperature. Brief exposure to 15°C to 30°C (59°F to 86°F) is allowed.

Source: Lexidrug, letermovir monograph (accessed 9/30/2026); Prevymis prescribing information, Merck Sharp & Dohme LLC, January 2026. This is not a complete list. Do not start, stop or change how you take Prevymis without talking to your transplant team.